EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieÄquivalenzstudieOpen Access · CC BY 4.0

Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1

Diego Ferone iD, Pamela Freda, Laurence Katznelson, Federico Gatto iD, Pinar Kadioğlu, Pietro Maffei, Jochen Seufert, Julie M Silverstein, Joanna L Spencer-Segal, Elena Isaeva, Alexander Dreval, Maria Harrie und 2 weitere

The Journal of Clinical Endocrinology & Metabolism · 19.05.2025 · 110 (6) · 1729-1739

DOI: 10.1210/clinem/dgae707 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 08.10.2024. Verfasst von Diego Ferone und 13 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Unit, Department of Internal Medicine, IRCCS Ospedale Policlinico San Martino, 16131 Genova, Italy. Hauptthemen laut MEDLINE: Acromegaly, Octreotide. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Camurus AB.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Acromegaly, characterized by excessive GH and insulin-like growth factor-1 (IGF-1), impacts quality of life (QoL) and mortality. Standard of care (SoC; octreotide long-acting repeatable or lanreotide autogel) treatment typically requires healthcare provider administration. CAM2029, a novel subcutaneous octreotide depot with increased bioavailability using FluidCrystal technology, enables self-administration and room-temperature storage.

Objective

Assess superiority of CAM2029 vs placebo for biochemical control in patients with controlled acromegaly.

Design

24-week, multinational, randomized, double-blind, phase 3 trial (NCT04076462).

Setting

45 sites; 10 countries. Patients 72 patients on SoC with biochemical control at screening [IGF-1 ≤upper limit of normal (ULN); mean GH <2.5 μg/L].

Interventions

Patients were randomized 2:1 to once-monthly CAM2029 (n = 48) or placebo (n = 24). Main Outcome Measures The primary endpoint was proportion of patients with IGF-1 ≤ULN (week 22/24 mean), with dose-reduced patients classified as nonresponders; first key secondary endpoint was the same, including dose-reduced responders. The second key secondary endpoint was proportion of patients with IGF-1 ≤ULN (week 22/24) and mean GH <2.5 μg/L (week 24).

Results

At week 22/24 (intention-to-treat analysis), CAM2029-treated patients demonstrated superior response rates vs placebo for IGF-1 (72.2% vs 37.5%; risk difference: 34.6, 95% confidence interval: 11.3, 57.9; P = .0018) and combined IGF-1/GH (70.0% vs 37.5%; P = .0035). CAM2029-treated patients had well-controlled symptoms, improved QoL, and treatment satisfaction vs placebo and baseline. CAM2029 was well tolerated; safety was consistent with SoC.

Conclusion

CAM2029 provides a convenient and effective treatment option for acromegaly, with superior biochemical control vs placebo. Symptom control, QoL, and satisfaction were improved from baseline SoC. Clinical Trial Registration NCT04076462 (ClinicalTrials.gov).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcromegalyOctreotideHumansDouble-Blind MethodFemaleMaleMiddle AgedInsulin-Like Growth Factor IAdultInjections, SubcutaneousQuality of LifeDelayed-Action PreparationsAgedHuman Growth HormoneTreatment Outcome

Stichwörter der Autor:innen

CAM2029FluidCrystalacromegalyoctreotiderandomized controlled trialsomatostatin receptor ligands

Substanzen

OctreotideInsulin-Like Growth Factor IDelayed-Action PreparationsHuman Growth HormoneIGF1 protein, human

Autor:innen und Institutionen

  • Endocrinology Unit, Department of Internal Medicine, IRCCS Ospedale Policlinico San Martino, 16131 Genova, Italy.
  • Department of Medicine, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY 10032, USA.
  • Departments of Medicine and Neurosurgery, Stanford University, Stanford, CA 94305, USA.
  • Division of Endocrinology-Metabolism and Diabetes, Department of Internal Medicine, Istanbul University-Cerrahpasa, 34303 Istanbul, Turkey.
  • Department of Medicine, Padua University Hospital, 35128 Padua, Italy.
  • Division of Endocrinology and Diabetology, Department of Medicine II, Medical Faculty, University of Freiburg, 79110 Freiburg, Germany.

ORCID-Profile: Diego Ferone, Federico Gatto, Fredrik Tiberg

Förderung

  • Camurus AB

Zitieren

APA

Ferone, D., Freda, P., Katznelson, L., Gatto, F., Kadioğlu, P., Maffei, P., Seufert, J., Silverstein, J. M., Spencer-Segal, J. L., Isaeva, E., Dreval, A., Harrie, M., Svedberg, A., & Tiberg, F. (2025). Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1. The Journal of Clinical Endocrinology & Metabolism, 110(6), 1729-1739. https://doi.org/10.1210/clinem/dgae707

Vancouver

Ferone D, Freda P, Katznelson L, Gatto F, Kadioğlu P, Maffei P, et al. Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1. The Journal of Clinical Endocrinology & Metabolism. 2025;110(6):1729-1739. doi:10.1210/clinem/dgae707

BibTeX
@article{Ferone2025,
  author = {Ferone, Diego and Freda, Pamela and Katznelson, Laurence and Gatto, Federico and Kadioğlu, Pinar and Maffei, Pietro and Seufert, Jochen and Silverstein, Julie M and Spencer-Segal, Joanna L and Isaeva, Elena and Dreval, Alexander and Harrie, Maria and Svedberg, Agneta and Tiberg, Fredrik},
  title = {Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  volume = {110},
  number = {6},
  pages = {1729--1739},
  doi = {10.1210/clinem/dgae707}
}
Kostenlos starten →